Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours

Journal of Pathology

Volumn 182, Issue 1, 1997, Pages 54-61

  Schlott, Thilo ^a   Reimer, Silke ^a   Jahns, Anke ^a   Ohlenbusch, Andreas ^a   Ruschenburg, Ilka ^a   Nagel, Holger ^a   Droese, Manfred ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

hepatocellular carcinoma; lymphoma; osteosarcoma; zinc finger

Indexed keywords

ONCOPROTEIN; PROTEIN P53; ZINC FINGER PROTEIN;

ARTICLE; CELL DIVISION; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE INSERTION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; BLOTTING, SOUTHERN; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; OSTEOSARCOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; ZINC FINGERS;

EID: 0030898754     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199705)182:1<54::AID-PATH815>3.0.CO;2-I     Document Type: Article

References (29)

1. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 1992; 358: 80-83.
2. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol Genet 1987; 13: 235-244.
3. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated With enhanced expression of a gene that is amplified in mouse tumor cell line. EMBO J 1991; 10: 1565-1569.
4. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
5. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
6. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimichi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
7. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogeneassociated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 1994; 91: 2026-2030.
8. Chen CY, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994; 91: 2684-2688.
9. Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994; 86: 1266-1267.
10. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alterations in human cancer: a review. Int J Cancer 1994; 57: 1-9.
11. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
12. Cordon-Carlo C, Laues E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 4: 794-799.
13. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
14. Murchetti A, Buttitta F, Girlando S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995; 175: 31-38.
15. Quesnel B, Preudhomme C, Oscier D, et al. Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol 1994; 88: 415-118.
16. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 6: 1608-1614.
17. Bueso-Ramos CE, Yang Y, DeLeon E, McCown P, Stass SA, Albithar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623.
18. Martinez JC, Mateo M, Sanchez-Beato M, et al. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 1995; 177: 27-34.
19. Albitar M, Peschle C, Liebhaber SA. Theta, zeta, and epsilon globin mRNAs are expressed in normal adults. Blood 1989; 74: 629-637.
20. Gonzalez IL, Gorski JL, Campen TJ, et al. Variation among human 28S ribosomal RNA genes. Proc Natl Acad Sci USA 1985; 82: 7666-7670.
21. Buddy MN, Freemont PS, Borden KLB. The p53-associated protein MDM2 contains a newly characterized zinc-finger domain called the RING finger. Trends Biochem Sci 1994; 19: 188-189.
22. Sanger F, Nicklen S, Coulsen AR. DNA sequencing with chain termination inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
23. Casanova JL, Pannetier C, Jaulin C, Kourilsky P. Optimal conditions for directly sequencing double-stranded PCR products with Sequenase. Nucleic Acid Res 1990; 18: 4028.
24. Cordell LJ, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complex of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 3: 219-229.
25. Satokata I, Tanaka K, Okada Y. Molecular basis of group A xeroderma pigmentosum: a missense mutation and two deletions located in a zinc finger consensus sequence of the XPAC gene. Hum Genet 1992; 88: 60-607.
26. Little MH, Presser J, Condie A, Smith PJ, VanHeiningen V, Hastie ND. Zinc fineer mutations within the WT1 nene in Wilms tumor patients. Proc Natl Acad Sci USA 1992; 89: 4791-4795.
27. Costa A, Marasca R, Valentinis B, et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995; 176: 45-53.
28. Haines DS, Landers JE, Engle LJ, George DI, Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 1994; 14: 1171-1178.
29. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transformation ability and frequent detection in human cancer. Nature Med 1996; 2: 912-917.